About US
Contact us
-
FDA to vote on opioid-induced constipation pillsTheFDAhas announced it will vote this week on whether a class of drugs that treat opioid-induced constipation needs more clinical testing in light of a side effect: heart attack. The class of drugs in2014/6/20
-
DARA BioSciences receives FDA orphan drug designation for KRN5500DARA BioSciences has received orphan drug designation from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for KRN5500, for treating multiple myeloma. Multiple myelo2014/6/19
-
Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms MarketPoor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been2014/6/19
-
With Pfizer's bid dead, AstraZeneca chief promises eyes on goalWith Pfizer's ($PFE) unwanted buyout bid in the past--at least for now--AstraZeneca ($AZN) needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted2014/6/18
-
The top 10 best-selling diabetes drugs of 2013Everybody knows that diabetes is an epidemic in this country that is costing lives and money. New stats from the U.S. Centers for Disease Control and Prevention (CDC) peg at 29.1 million the number of2014/6/18
-
Bayer’s Gadavist injection cleared for breast cancer evaluationThe US Food and Drug Administration (FDA) has approved Bayer HealthCare's Gadavist (gadobutrol) injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the US. The2014/6/17
-
FDA grants priority review for Abbvie’s hepatitis C therapy new drug applicationThe US Food and Drug Administration (FDA) has accepted and granted priority review to AbbVie's new drug application for its interferon-free regimen to treat adult patients with chronic genotype 1 (GT12014/6/17
-
AstraZeneca signs licence agreement with Synairgen for asthma drugAstraZeneca has signed an exclusive global licence agreement for rights to Synairgen's SNG001, an inhaled interferon beta in clinical development for treating respiratory tract viral infections in pat2014/6/16
-
Janssen and ViiV Healthcare to develop two-drug single tablet regimen for HIV-1Janssen R&D Ireland and ViiV Healthcare have announced a collaboration to develop and commercialise a new single tablet regimen containing Janssen's rilpivirine and ViiV's dolutegravir as the sole2014/6/16
-
Scottish Medicines Consortium approves Defitelio for haematopoietic stem cell transplantationDrug approval body Scottish Medicines Consortium (SMC) has authorised Defitelio (defibrotide) for use as a supportive treatment for haematopoietic stem cell transplantation (HSCT) in treating patients2014/6/13